The improvements stem from the introduction of myeloid cells into our humanized mice, resulting in a more robust model. Notably, we now observe stable and persistent anti-dsDNA antibody levels in peripheral blood from week 4 to week 12 post-Pristane injection. Additionally, B and T cell populations are more stable, enabling more reliable evaluation of therapeutics targeting these cells. In our internal validation study using Rituximab, we observed a significant reduction in both dsDNA levels and human IgG deposition in kidney glomeruli in Rituximab-treated mice compared to saline controls.